Entering text into the input field will update the search result below

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q4 2020 Results - Earnings Call Transcript

Mar. 09, 2021 12:07 PM ETGamida Cell Ltd. (GMDA)
SA Transcripts profile picture
SA Transcripts

Gamida Cell Ltd. (NASDAQ:GMDA) Q4 2020 Results Conference Call March 9, 2021 8:30 AM ET

Company Participants

Josh Hamermesh - Chief Business Officer

Julian Adams - CEO

Ronit Simantov - Chief Medical Officer

Shai Lankry - CFO

Michele Korfin - COO and Chief Commercial Officer

Tracey Lodie - Chief Scientific Officer

Conference Call Participants

Ted Tenthoff - Piper Sandler

Jonathan Miller - Evercore ISI

Roy Buchanan - JMP Securities

Gregory Renza - RBC Capital Markets

Mark Breidenbach - Oppenheimer

Gil Blum - Needham & Company


Ladies and gentlemen, thank you for standing by. Welcome to Gamida Cell’s Conference Call for the Full Year Financial 2020 Results. My name is Brandi, and I’ll be your operator for today’s call. Please be advised that this call is being recorded at Gamida Cell’s request.

Now, I would like to introduce your host for today’s conference, Mr. Josh Hamermesh, Chief Business Officer. Please go ahead.

Josh Hamermesh

Thank you, Brandi, and good morning, everyone. Welcome to today’s call, during which we will provide an update on the Company and review our financial results for the full year of 2020.

Earlier this morning, we issued a press release summarizing our financial results and progress across the Company, which is available on our website at www.gamida-cell.com. Here with me on our call today are Julian Adams, Chief Executive Officer; Ronit Simantov, Chief Medical Officer; and Shai Lankry, Chief Financial Officer. Michele Korfin, our Chief Operating Officer and Chief Commercial Officer; and Tracey Lodie, our Chief Scientific Officer, are also on hand for the Q&A portion of the call following our prepared remarks.

During this call, we may make forward-looking statements about our future expectations and plans, including clinical development and commercial objectives, the therapeutic potential of our product candidates, our operational plans and strategies, and projected operating expenses and cash

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About GMDA

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on GMDA

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.